Jonathan A. Schur

jonathan-schur

Jonathan A. Schur

Counsel

New York | 1095 Avenue of the Americas, New York, NY 10036-6797
+1 212 698 3552 | +1 212 698 3599

| vCard | PDF

Jonathan Schur advises pharmaceutical and medical device companies in structuring mergers and acquisitions, divestitures, licensing and distribution arrangements, joint ventures, and cooperative development and marketing relationships. For example, he advised a multinational company on a successful strategy for acquiring the supplier of one of its key products. Mastery of regulatory requirements and litigation risks was critical to the acquisition strategy. He has advised many buyers making strategic acquisitions in France and Europe on how to focus their due diligence and how to draft agreements to resolve potential problems that are unique in these jurisdictions.

Mr. Schur is particularly known for his ability to bring parties of transactions together so that the legal and cultural gulfs between European and U.S. companies can be bridged effectively. He also works with clients to arrange venture and later-stage financing, as well as representing them pre-IPO and at the IPO stage.

Companies intending to enter the French and European market are likewise counseled on both legal and management issues that need to be addressed to ensure efficient operations and achieve regulatory compliance. This includes the regulatory aspects of product and pricing authorizations, clinical trials, agreements with hospitals and physicians, privacy and marketing practices in the life sciences sector.

Listed in Chambers Europe 2012 for Pharma-Life Sciences Corporate in France, “dual U.S. and French qualified Jonathan Schur has a strong corporate and regulatory background. He regularly advises pharma and medical device clients on M&A and joint ventures.” In addition, Mr. Schur is listed by The Legal 500 (U.S.) for life sciences, where he is cited as being “highly skilled and committed.” He is also recommended by Practical Law Company’s “Which Lawyer?” guide for both Regulatory and Corporate matters.

Significant Representations

  • A Copenhagen-based biopharmaceutical company in negotiation of an exclusive global license and collaboration agreement with one of the world’s leading pharmaceutical companies.
  • A Japanese pharmaceutical company in connection with a European commercialization agreement for an oncology product.
  • A Copenhagen-based biopharmaceutical company in negotiation of an exclusive development and license agreement with a major European pharmaceutical company.
  • A French biopharmaceutical company in connection with a distribution agreement with an American company.
  • A Copenhagen-based biopharmaceutical company in its IPO, one of the largest European IPOs in the life sciences sector in several years.
  • A U.S.-based medical products manufacturer in its acquisition of the drug delivery device business assets of a French company.
  • A Copenhagen-based biopharmaceutical company in a drug discovery agreement with an Australian/American biotechnology company.
  • A Japanese pharmaceutical company in connection with an ICC arbitration concerning a sale of a marketing authorization.
  • A Copenhagen-based biopharmaceutical company in a licensing agreement for a late stage product with one of the world’s leading pharmaceutical companies.
Education
  • Harvard College, A.B., 1975, cum laude
  • Harvard Law School, J.D., 1978, cum laude
Admissions
  • New York
  • Paris
Languages
  • English
  • French
Memberships
Former Trustee, The American Library in Paris, Inc.
Former President, Harvard Law School Association of France
Former Administrative Director, Union Internationale des Avocats